Nitric oxide-epoxygenase interactions and arachidonate-induced dilation of rat renal microvessels

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 285, Issue 5 54-5, 2003, Pages

  Udosen, I T ^a   Jiang, H ^b   Hercule, H C ^a   Oyekan, A O ^a  

^a TEXAS SOUTHERN UNIVERSITY   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Cytochrome P 450; Epoxides; Vasodilation

Indexed keywords

1 (2 HYDROXY 5 TRIFLUOROMETHYLPHENYL) 5 TRIFLUOROMETHYL 2(3H) BENZIMIDAZOLONE; 11,12 EPOXY 5,8,14 ICOSATRIENOIC ACID; 14,15 EPOXY 5,8,11 ICOSATRIENOIC ACID; 18ALPHA GLYCYRRHETINIC ACID; 5,6 EPOXY 8,11,14 ICOSATRIENOIC ACID; 8 BROMO CYCLIC GMP; 8,9 EPOXYICOSATRIENOIC ACID; APAMIN; ARACHIDONIC ACID; ARACHIDONIC ACID DERIVATIVE; BRADYKININ; CALCIUM ACTIVATED POTASSIUM CHANNEL; CROMAKALIM; CYCLIC GMP; CYTOCHROME P450; CYTOCHROME P450 EPOXYGENASE; ENZYME INHIBITOR; EPOXIDE; HEMOPROTEIN; HEXANOIC ACID DERIVATIVE; HYDRALAZINE; MICONAZOLE; NITRIC OXIDE; NITRIC OXIDE DONOR; NITROPRUSSIDE SODIUM; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL STIMULATING AGENT; PROSTANOID; SPERMINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARACHIDONIC ACID METABOLISM; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; EXCITATION CONTRACTION COUPLING; GAP JUNCTION; KIDNEY BLOOD VESSEL; MALE; MICROVASCULATURE; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; RAT; SECOND MESSENGER; SIGNAL TRANSDUCTION; VASODILATATION;

EID: 0142169987     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00075.2003     Document Type: Article

References (41)

1. Alonso-Galicia M, Drummond HA, Reddy KK, Falck JR, Harder DR, and Roman RJ. Inhibition of 20-HETE production contributes to the vascular responses to nitric oxide. Hypertension 29: 320-325, 1997.
2. + channels. Eur J Pharmacol 361: 43-49, 1998.
3. Bauersachs J, Popp R, Hecker M, Sauer E, Fleming I, and Busse R. Nitric oxide attenuates the release of endothelium-derived hyperpolarizing factor. Circulation 94: 3341-3347, 1996.
4. Beny JL and Brunet PC. Neither nitric oxide nor nitroglycerin accounts for all the characteristics of endothelially mediated vasodilation of pig coronary arteries. Blood Vessels 25: 308-311, 1988.
5. Campbell WB, Gebremedhin D, Pratt PF, and Harder DR. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res 78: 415-423, 1996.
6. Carlson TJ and Billings RE. Role of nitric oxide in the cytokine-mediated regulation of cytochrome P450. Mol Pharmacol 49: 796-801, 1996.
7. Cohen RA and Vanhoutte PM. Endothelium-dependent hyperpolarization beyond nitric oxide and cyclic GMP. Circulation 92: 3337-3349, 1995.
8. Ca channel opener, in vascular smooth muscle. Br J Pharmacol 113: 1538-1547, 1994.
9. Fisslthaler B, Hinsch N, Chataigneau T, Popp R, Kiss L, Busse R, and Fleming I. Nifedipine increases CYP2C expression and endothelium-derived hyperpolarizing factor-mediated responses in coronary arteries. Hypertension 36: 270-275, 2000.
10. Frisbee JC, Roman RJ, Krishna UM, Falck JR, and Lombard JH. Relative contribution of cyclooxygenase and cytochrome P450 ω -hydroxylase-dependent pathways to hypoxic dilation of skeletal muscle resistance arteries. J Vasc Res 38: 305-314, 2001.
11. Fulton D, McGiff JC, and Quilley J. Contribution of NO and cytochrome P450 to the vasodilator effect of bradykinin in the rat kidney. Br J Pharmacol 107: 722-725, 1992.
12. Fulton D, McGiff JC, and Quilley J. Pharmacological evaluation of an epoxide as the putative hyperpolarizing factor mediating the nitric oxide-independent vasodilator effect of bradykinin in the rat heart. J Pharmacol Exp Ther 287: 497-503, 1998.
13. Fulton D, McGiff JC, and Quilley J. Role of potassium channels in the vasodilator responses to bradykinin in the rat heart. Br J Pharmacol 113: 954-958, 1994.
14. Hecker M, Bara AT, Bauersachs J, and Busse R. Characterization of endothelium-derived hyperpolarizing factor as a cytochrome P450-derived arachidonic acid metabolite in mammals. J Physiol 481: 407-414, 1994.
15. Hutcheson IR, Chaytor AT, Evans WH, and Griffith TM. Nitric oxide-independent relaxations to acetylcholine and A23187 involve different routes of heterocellular communication. Role of Gap junctions and phospholipase A2. Circ Res 84: 53-63, 1999.
16. Imig JD, Falck JR, Wei S, and Capdevilla JH. Epoxygenase metabolites contribute to nitric oxide-independent afferent arteriolar vasodilation in response to bradykinin. J Vasc Res 38: 247-255, 2001.
17. Imig JD, Navar LG, Roman RJ, Reddy KK, and Falck JR. Actions of epoxygenase metabolites on the preglomerular vasculature. J Am Soc Nephrol 7: 2364-2370, 1996.
18. Karara A, Makita K, Jacobson HR, Falck JR, Guengerich FP, DuBois RN, and Capdevilla JH. Molecular cloning, expression, and enzymatic characterization of the rat kidney cytochrome P-450 arachidonic acid epoxygenase. J Biol Chem 268: 13565-13570, 1993.
19. Khatsenko OG, Gross SS, Rifkind AB, and Vane JR. Nitric oxide is a mediator of the decrease in cytochrome P450-dependent metabolism caused by immunostimulants. Proc Natl Acad Sci USA 90: 11147-11151, 1993.
20. McGiff JC. Cytochrome P-450 metabolism of arachidonic acid. Annu Rev Pharmacol Toxicol 31: 339-369, 1991.
21. Mombouli JV and Vanhoutte PM. Endothelium-derived hyperpolarizing factor(s): updating the unknown. Trends Pharmacol Sci 18: 252-256, 1997.
22. Nishikawa Y, Stepp DW, and Chilian WM. Nitric oxide exerts feedback inhibition on EDHF-induced coronary arteriolar dilation in vivo. Am J Physiol Heart Circ Physiol 279: H459-H465, 2000.
23. Oltman CL, Kane NL, Fudge JL, Weintraub NL, and Dellsperger KC. Endothelium-derived hyperpolarizing factor in coronary microcirculation: responses to arachidonic acid. Am J Physiol Heart Circ Physiol 281: H1553-H1560, 2001.
24. Onoue H and Katusic ZS. Role of potassium channels in relaxations of canine middle cerebral arteries induced by nitric oxide donors. Stroke 28: 1264-1270, 1997.
25. Oyekan AO, Balazy M, and McGiff JC. Renal oxygenases: differential contribution to vasoconstriction induced by endothelin-1 and angiotensin II. Am J Physiol Regul Integr Comp Physiol 273: R293-R300, 1997.
26. Oyekan AO and McGiff JC. Functional response of the rat kidney to inhibition of nitric oxide synthesis: role of cytochrome P450-derived arachidonate metabolites. Br J Pharmacol 125: 1065-1073, 1998.
27. Oyekan AO, McGiff JC, and Quilley J. Cytochrome P-450-dependent vasodilation of rat kidney by arachidonic acid. Am J Physiol Heart Circ Physiol 261: H714-H719, 1991.
28. Oyekan AO, Youseff T, Fulton D, Quilley J, and McGiff JC. Renal cytochrome P450 ω-hydroxylase and epoxygenase activity is differentially modified by nitric oxide and NaCl. J Clin Invest 104: 1131-1137, 1999.
29. Quilley J, Fulton D, and McGiff JC. Hyperpolarizing factors. Biochem Pharmacol 54: 1059-1070, 1997.
30. Rapacon M, Mieyal P, McGiff JC, Fulton D, and Quilley J. Contribution of calcium activated potassium channels to the vasodilator effect of bradykinin in the isolated perfused kidney of the rat. Br J Pharmacol 118: 1504-1508, 1996.
31. Sandow SL, Tare M, Coleman HA, Hill CE, and Parkington HC. Involvement of myoendothelial gap junctions in the action of endothelium-derived hyperpolarizing factor. Circ Res 90: 1108-1113, 2002.
32. Santicioli P and Maggi CA. Effect of 18β-glycyrrhetinic acid on electromechanical coupling in the guinea pig renal pelvis and ureter. Br J Pharmacol 129: 163-169, 2000.
33. Schildmeyer LA and Bryan RM. Effect of NO on EDHF response in rat middle cerebral arteries. Am J Physiol Heart Circ Physiol 282: H734-H738, 2002.
34. Sewer MB, Koop DR, and Morgan ET. Endotoxemia in rats is associated with induction of the P450A subfamily and suppression of several other forms of cytochrome P450. Drug Metab Dispos 24: 401-407, 1996.
35. + channel activity and vascular tone in renal arterioles. Circ Res 83: 1069-1079, 1998.
36. Takemura S, Minamiyama Y, Imaoka S, Funae Y, Hirobashi K, Inoue M, and Kinoshita H. Hepatic cytochrome P450 is directly inactivated by nitric oxide not by inflammatory cytokines, in the early phase of endotoxemia. J Hepatol 30: 1035-1044, 1999.
37. Tare M, Parkington HC, Coleman HA, Neild TO, and Dusting GJ. Hyperpolarization and relaxation of arterial smooth muscle caused by nitric oxide derived from the endothelium. Nature 346: 69-71, 1990.
38. Wang MH, Brand-Schieber E, Zand B, Nguyen X, Falck JR, Balu N, and Schwartzman ML. Cytochrome P450-derived arachidonic acid metabolism in the rat kidney: characterization of selective inhibitors. J Pharmacol Exp Ther 284: 966-973, 1998.
39. Wang X and Loutzenhiser R. Determinants of renal microvascular response to ACh: afferent and efferent arteriolar actions of EDHF. Am J Physiol Renal Physiol 282: F124-F132, 2002.
40. Widmann MD, Weintraub NL, Fudge JL, Brooks LA, and Dellsperger KC. Cytochrome P-450 pathway in acetylcholine-induced canine coronary microvascular vasodilation in vivo. Am J Physiol Heart Circ Physiol 274: H282-H289, 1998.
41. Wink DA, Osawa Y, Derbyshire JF, Jones CR, Eshenaur SC, and Nims RW. Inhibition of cytochromes P450 by nitric oxide and a nitric oxide releasing agent. Arch Biochem Biophys 310: 115-123, 1993.